Maggie L. Shaw

On September 19, the FDA handed down its third amivantamab (Rybrevant; Johnson & Johnson) approval for 2024 in non–small cell lung cancer (NSCLC), giving the third-generation tyrosine kinase inhibitor its fourth approval overall.

This interview accompanies the fourth podcast in our National Recovery Month series with Amy Herschell, PhD, associate vice president, Program Implementation and Evaluation, Community Care Behavioral Health Organization, part of the UPMC Insurance Services Division, and Jessica Meyers, MSEd, senior advisor for implementation, UPMC Center for High-Value Health Care.

The approval means an additional indication for osimertinib (Tagrisso; AstraZeneca) for adult patients who have unresectable stage III non–small cell lung cancer (NSCLC) with EGFR mutation.

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our fourth episode, we speak with Amy Herschell, PhD, and Jessica Meyers, MSEd.

The phase 1/2 SAINT study is currently investigating intravenous trabectedin plus ipilimumab and nivolumab in the first line for advanced soft tissue sarcoma.

This interview accompanies the third podcast in our National Recovery Month series with Kim MacDonald-Wilson, ScD, CPRP, senior program director, Recovery and Wellness Transformation, and Tracy Carney, CPS, CPRP, senior recovery and resiliency specialist, Community Care Behavioral Health Organization.

The Inflation Reduction Act was signed into law on August 16, 2022, and the debate over its Medicare-related benefits and impact on the prescription drug market has been raging ever since.

The principal goal of therapies for multiple myeloma, which remains incurable, is to extend progression-free survival, but challenges remain bringing chimeric antigen receptor T-cell therapy to the world, explains Leland Metheny, MD, lead investigator for the phase 1 BAFF CAR T clinical trial, University Hospitals Seidman Cancer Center.

Here we conclude our discussion with David P. Carbone, MD, PhD, The Ohio State University, by addressing the importance of both advocacy for and education on biomarker testing in the lung cancer space.

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In this third episode, we speak with Kim MacDonald-Wilson, ScD, CPRP, and Tracy Carney, CPS, CPRP.

In a session at AIDS 2024, the International AIDS Conference, global leaders and community advocates gathered to discuss why stigma and shame continue to attach themselves to an HIV diagnosis and why policy efforts to overcome both must persist.

Here are 5 areas of specialty care that rural communities often lack, putting them at a distinct disadvantage for optimal short- and long-term health outcomes and highlighting inequitable access to care for those often living in economically disadvantaged areas.

This interview accompanies the second podcast in our National Recovery Month series with Mandy Faubel, PhD, LCSW, UPMC Western Behavioral Health at Safe Harbor, and Rebekah Sedlock, DSW, LCSW, UPMC Insurance Services Division with Community Care.

Research presented at the 2024 European Society of Cardiology Congress explored gender-based care and outcomes disparities, with potential implications for health care policy and equitable care of women and men in secondary disease prevention.

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In this second episode, we speak with Rebekah Sedlock, DSW, LCSW, and Mandy Fauble, PhD, LCSW.

At the 2024 European Society of Cardiology Congress (ESC), key research in cardiology care included studies conducted on cardiovascular disease risk among women, cardiac distress and smoking, and lipoprotein(a).

This interview accompanies the first podcast in our National Recovery Month series with Michael Lynch, MD, attending emergency physician and medical toxicologist at the University of Pittsburgh Medical Center.

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In this first episode, we speak with Michael Lynch, MD, associate professor of emergency medicine at the University of Pittsburgh and an attending emergency physician and medical toxicologist at the University of Pittsburgh Medical Center.

Finerenone's approval by the FDA to treat type 2 diabetes–associated chronic kidney disease was supported by data from the phase 2 FIDELIO-DKD trial; now, the results of FINEARTS-HF show real-world application for patients living with heart failure with preserved ejection fraction or mildly reduced ejection fraction.

The obesity epidemic is a global crisis, with experts from around the world emphasizing the importance of short-term strategies, long-term solutions, and multidisciplinary collaboration as they advocate for the heart health of their patients.

At the 25th International AIDS Conference, Emmanuel Nazaire Essam, MD, MPH, presented the analysis, "Medicaid Insurance Expansion and Its Association With HIV Outcomes in Nebraska, USA: An Observational Prospective Cohort Study."

David Thompson, PhD, Queen’s University Belfast, expands on previous research he conducted that calls for cardiovascular health care providers to actively address care inequities evident in practice and policy.

A joint session from the European Society of Cardiology and the World Heart Federation examined the impact of noise, climate change, and air pollution on cardiovascular disease.

Pregnant and postpartum women who have cardiovascular (CV) disease represent a high-risk group of patients who require specialized care and intense monitoring for optimal health of them and their baby.

New STEP-HFpEF findings presented at this year’s European Society of Cardiology Congress add to the many accolades this glucagon-like peptide-1 receptor agonist has already received for the numerous benefits it can produce among patients living with heart failure with preserved ejection fraction.

This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody.

In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma.

The European Society of Cardiology (ESC) Congress 2024 will take place in London, England, August 30 to September 2.

Also known as coal workers’ pneumoconiosis, black lung disease (or miner’s lung) is typically the result of inhaling coal dust for many years that causes scarring in the lungs and makes breathing increasingly difficult. The prevalence of black lung has been on the rise in the US.

Leland Metheny, MD, is lead investigator for the Phase 1 BAFF CAR T clinical trial, which is evaluating the safety and effectiveness of a novel approach to chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) that targets 3 receptors on cancer cells and uses electroporation vs the typical lentiviral vector delivery.